Journals / Turkish Journal of Endocrinology and Metabolism / 2017 / Cilt: 21 - Sayı: 3

Çoklu Kanseri Olan Bir Hastada Kalıntı Ablasyonu Sonrası Ağırlaşmış Orbitopati

Aggravated Orbitopathy Following Remnant Ablation in a Patient with Multiple Cancers

Pages
81–84
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aggravation of orbitopathy can be observed following remnant ablation for thyroid cancer in patients with Graves' disease, and glucocorticoid prophylaxis may be considered in patients with active Graves' orbitopathy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The rate of thyroid cancer in the patients with Graves' disease is controversial.
📊
Key Findings & Data:A 53-year-old non-smoker female was diagnosed with Graves' disease and underwent total thyroidectomy after the eye ?ndings became more evident two months after the initiation of an anti-thyroid drug.
💡
Conclusion & Impact:The aggravation of orbitopathy can be observed following remnant ablation for thyroid cancer in patients with Graves' disease, and glucocorticoid prophylaxis may be considered in patients with active Graves' orbitopathy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The rate of thyroid cancer in the patients with Graves' disease is controversial. The rare incidents of multiple primary thyroid cancers in the same patient have been reported. The coexistence of multiple primary thyroid cancers in patients with autoimmune thyroiditis is even rarer. The eye ?n- dings may worsen following radioactive iodine (RAI) therapy for thyrotoxicosis in Graves' disease. In this case report, we present a patient with Gra- ves' disease with a pathological diagnosis of papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) having aggravated orbitopathy following remnant ablation. A 53-year-old non-smoker female was diagnosed with Graves' disease and underwent total thyroidectomy after the eye ?ndings became more evident two months after the initiation of an anti-thyroid drug. The patient was pathologically diagnosed as having an underlying 3-cm FTC and 3-mm PTC. Furthermore, the patient received 100 mCi of RAI under steroid cover for the remnant ablation. The patient did not comply with the glu- cocorticoid therapy and the eye ?ndings were aggravated, thus requiring orbital decompression therapy. The aggravation of orbitopathy can be observed following remnant ablation for thyroid cancer in patients with Graves' disease, and glucocorticoid prophylaxis may be considered in patients with active Graves' orbitopathy.

Özet

Graves hastalığı olanlarda tiroid kanseri hızı tartışmalı bir durumdur. Aynı hastada çoklu birincil tiroid kanserlerin nadir insidansı olduğu raporlan- mıştır. Otoimmun tiroiditi olan kişilerde çoklu birincil tiroid kanserin eş zamanlı görülmesi daha da ender karşılaşılan bir durumdur. Graves hasta- lığında izlenen tirotoksikoz için yapılan radyoaktif iyodin (RAI) tedavisini takiben göz bulguları kötüleşebilir. Bu olgu sunumunda papiller troid (PTC) ve folliküler troid kanserinin (FTC) patolojik olarak tanısını almış Graves hastalığı olan bir kişide kalıntı ablasyonu sonrasında ağırlaşan orbitopati raporlanmıştır. 53 yaşında sigara içmeyen kadın hasta Graves hastalığı tanısı almış ve antitroid ilaç başlanmasından iki ay sonra göz bulgularının ağırlaşması ne- deniyle total troidektomi geçirmiştir. Hasta patolojik olarak 3 cm FTC ve 3 mm PTC olarak tanı almıştır. Kalıntı ablasyonu için steroid kılıf altında 100 mCi RAI uygulanmıştır. Glukokortikoid tedavisine uyum sağlayamamış ve göz bulguları ağırlaştığı için orbital dekompresyon tedavisi yapılmıştır. Orbitopatinin ağırlaşması Graves hastalığı olan hastalarda troid kanseri için kalıntı ablasyonunu takiben izlenebilen bir durumdur. Glukokortikoid pro?aksisi aktif Graves orbitopatisi olan kişilerde düşünülebilir.

🔖

Cite This Article

MOUSA, U., SAV, H., KÖSEOĞLULARI, O., AYDIN, Ş., ÖZKAYALAR, H. (2017). Çoklu Kanseri Olan Bir Hastada Kalıntı Ablasyonu Sonrası Ağırlaşmış Orbitopati. Turkish Journal of Endocrinology and Metabolism, Cilt: 21 - Sayı: 3, 81–84. https://ajindex.com/articles/370766

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Kraimps JL, Bouin-Pineau MH, Mathonnet M, De Calan L, Ronceray J, Visset J, Marechaud R, Barbier J. Multicentre study of thyroid nodules in patients with Graves' disease. Br J Surg. 2000;87:1111-1113
  2. Tam AA, Kaya C, Kılıç FB, Ersoy R, Çakır B. Thyroid nodules and thyroid cancer in Graves' disease. Arq Bras Endocrinol Metabol. 2014;58:933-938
  3. Wei S, Baloch ZW, LiVolsi VA. Thyroid carcinoma in patients with Graves' disease: an institutional experience. Endocr Pathol. 2015;26:48-53
  4. Mousa U, Tutuncu NB. Hashimoto tiroiditi olan diyabetik bir vakada foliküler ve papiller karsinomu birlikteliği. Journal of Dialog in Endocrinology. 2012;9:193-195
  5. Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Morcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM. Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158:273-285
  6. Boutzios G, Vasileiadis I, Zapanti E, Charitoudis G, Karakostas E, Leromonachou P, Karatzas T. Higher incidence of tall cell variant of papillary thyroid carcinoma in Graves' disease. Thyroid. 2014;24:347-354
  7. Chou SJ, Yu JC, Liu YC, Hsieh CB, Chen A, Leu FJ. Synchronous bilateral varied histology in thyroid carcinoma. J Med Sci. 2004;24:47-48
  8. Darwish A, Satir AA, Hameed T, Malik S, Aqel N. Simultaneous medullary carcinoma, occult papillary carcinoma and lymphocytic thyroiditis. Malays J Pathol 1995;17:103- 107
  9. Moleti M, Violi MA, Montanini D, Trombetta C, Di Bella B, Sturniolo G, Presti S, Alibrandi A, Campennì A, Baldari S, Trimarchi F, Vermiglio F. Radioiodine ablation of postsurgical thyroid remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-tosevere graves' orbitopathy (GO): a prospective, randomized, singleblind clinical trial. J Clin Endocrinol Metab. 2014;99:1783-1789
  10. Menconi F, Marinò M, Pinchera A, Rocchi R, Mazzi B, Nardi M, Bartalena L, Marcocci C. Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab. 2007;92:1653-1658
  11. Daumerie C, Boschi A, Perros P. Is recombinant human TSH a trigger for Graves' orbitopathy? Eur Thyroid J. 2012;1:105-109
  12. Berg G, Andersson T, Sjödell L,